In China, primary research drugs Icotinib and Endostar33–35 are used to instead of other first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and bevacizumab, because studies have shown that they are as effective as EGFR-TKI and bevacizumab in lung cancer patients in China36,37. The gene discussed is EGFR; the disease is lung cancer.